Long non-coding RNAs (lncRNAs) have been found to be involved in the pathogenesis of coronary artery disease (CAD). However, it remains to be established whether or not circulating lncRNAs can serve as biomarkers of CAD.
Introduction
Cardiovascular disease (CVD) is the leading cause of morbidity and mortality worldwide. Among CVDs, atherosclerosis (AS) and its thrombotic complications are the major causes. 1 Current therapeutic strategies, including reducing plasma low-density lipoprotein (LDL), antiplatelet agents, anticoagulants, percutaneous coronary intervention, and coronary artery bypass surgery, have been proved to be effective. However, the mortality has remained dismal because of the difficulty in making an early diagnosis of coronary artery disease (CAD). Therefore, the development of a new non-invasive method that can diagnose CAD early in its onset is critical in improving its prognosis.
Over the past few decades, developments in genome-wide analyses have identified that almost all of the human genomes are transcribed with a large number of long non-coding RNAs (lncRNAs). 2, 3 LncRNAs, ranging from 200 to over 10 000 nucleotides, lack the coding ability for protein. 4, 5 Many lncRNAs have been shown to be functional and are involved in specific physiological and pathological processes through epigenetics and transcriptional or post-transcriptional regulatory mechanisms. 6 -8 Recently, several studies have shown that lncRNAs are involved in the development of various pathological conditions, including cancers, 9 autoimmune diseases, 10, 11 and neurological disorders. 12 Some lncRNAs are also involved in the development of CVDs, 13 -15 including heart failure, 16 -18 cardiac hypertrophy, 19, 20 cardiometabolic diseases, 21 myocardial infarction, 22 and AS. 23 -25 Moreover, lncRNAs have been used as biomarkers for many diseases. For example, a prostate-specific lncRNA PCA3 in urine is used to detect prostate cancer. 26, 27 Other lncRNAs used as biomarkers include circulating H19 for gastric cancer, 28 lncRNA HULC in hepatocellular carcinoma, 29 and lncRNA LIPCAR in heart failure after myocardial infarction. 16 In this study, we determined whether or not certain circulating lncRNAs can be specific CAD biomarkers. CAD is considered as a chronic inflammatory disease that causes the formation of plaques in large-and mid-sized arteries. Many studies have indicated that circulating peripheral blood monocyte cells (PBMCs), which constitute 5-10% of peripheral blood leucocytes, by migrating into the arterial wall and increasing the size of atherosclerotic, play a pivotal role in the development of CAD. 30 -32 Therefore, our current study was initiated and designed to determine whether there were differences in lncRNAs of the PBMCs between CAD patients and control subjects and to study their diagnostic value as a biomarker of CAD.
Methods

Study population
This study is a single-centre Third MMU-based National Institute of Healthsponsored study (NIH.gov clinical trial NCT01629225). Briefly, the study recruited 502 patients admitted to the Department of Cardiology, Daping Hospital (Chongqing, China) from February 2013 to May 2014, for clinically diagnosed or suspected CAD. The study was approved by the Ethics Committee of the Medical Faculty of Daping Hospital. Written informed consent was obtained from all patients or their families in accordance with the Declaration of Helsinki. Diagnosis of CAD was based on the final diagnosis at discharge, according to the ACC/AHA classification. 33 According to published guidelines, 34 the percentage narrowing of coronary artery segments in angiograms was estimated by visual assessment from two independent interventional cardiologists in a blinded fashion, and differences were resolved by consensus. The diagnosis of CAD was based on the percentage narrowing of each coronary artery segment, with .50% stenosis of at least one of the major coronaries (the left main coronary trunk, anterior descending branch, circumflex artery, and right coronary artery). The controls were patients with no arterial stenosis at any of the coronary arteries. We used treadmill exercise tests to assess for CAD risk according to the Bruce protocol; 35 only those patients with negative results from treadmill exercise tests were included as control subjects (for detailed information of the treadmill exercise test for both groups, see Supplementary material online, Table S1 ). Moreover, we also used Morise CAD probability score to screen for CAD-positive patients. 36 Those subjects with high score (.15 points) and intermediate scores (scores [8] [9] [10] [11] [12] [13] [14] [15] were included in the patient group. Similarly, suspected patients with low score (,8 points) were excluded from the patient group, which means that those subjects with score .8 (including scores [8] [9] [10] [11] [12] [13] [14] [15] were included in the patient group. To minimize the potential influence of the presence of profound acute myocardial ischaemia, patients with myocardial infarction were excluded. Further exclusion criteria in this study were as follows: (i) patients with severe valvular heart disease, malignant tumours, and other severe systemic diseases (such as renal failure and hepatic disease); (ii) patients with serious acute infection in the previous 4 weeks or active chronic inflammatory disease, suspected drug, or alcohol abuse; and (iii) patients who rejected participation in this study.
Preparation of blood samples and purification of PBMCs
Blood sample (8 mL) from each patient, before angiography, was collected into a commonly used test tube containing EDTA. One millilitre of this peripheral blood was incubated in the dark for 15 min with 15 mL of fluorochrome-labelled monoclonal anti-human mouse antibody of PerCP-CD14 (BD Biosciences, Franklin Lake, NJ, USA). Sequentially, 10 mL of ammonium chloride lysing buffer was added to lyse red blood cells and 15 min later, 15 mL of staining medium [phosphate-buffered saline (PBS) with 3% heat-inactivated serum and 0.1% sodium azide] was added to stop the lysing reaction. After mixing gently, the samples were centrifuged at 120 g for 5 min and then washed five times with PBS. Thereafter, the cells were re-suspended in 200 mL of staining medium, mixed, and then immediately sorted by a fluorescence-activated cell sorting flow cytometer (FC500, Beckman Coulter, Fort Lauderdale). After at least 5 million monocytes were obtained by the cytometer, flow data were analysed using Flowjo software (Treestar, Inc.). Absolute mononuclear cell count was estimated as the sum of monocytes using a Coulter ACT/Diff cell counter (Beckman Coulter).
RNA isolation and quantitative RT-PCR
Total RNA was extracted from the plasma, PBMCs, and THP-1, using TRIzol (Invitrogen, NY, USA), 29, 37 and purified with RNeasy kits (Qiagen, Hilden, Germany). After reverse transcription (Superscript II, Invitrogen), quantitative PCR (qPCR) was performed using Brilliant SYBR Green Mastermix-Kit and MX4000 multiplex qPCR System from Stratagene. The primers used in the qPCR of lncRNAs were listed in Supplementary material online, Table S2 . All measurements were performed in triplicate. LncRNA expression levels were normalized against the housekeeping gene, beta-actin (ACTB). Plate-to-plate variations of transcript expression levels were normalized by quantile normalization.
Microarray and computational analysis
RNAs from plasma and PBMCs were subjected to microarray-based global transcriptome analysis. RNA was pre-amplified and then underwent microarray analysis (Arraystar, Human lncRNA array, version 2.0), which allowed the simultaneous detection of 33 045 lncRNAs and 30 215 coding transcripts. To find a potential biomarker candidate lncRNA, we first screened all lncRNA transcripts in the lncRNA microarrays. To make lncRNA levels easily detectable in the clinic, we selected lncRNAs with abundant expression and up-regulation in CAD patients, according to the following criteria: fold change .2 and P , 0.05. After screening, 51 lncRNA transcripts were found to be up-regulated (see Supplementary material online, Table S3 ).
The microarray data analysed in this study were deposited in the NCBI Gene Expression Omnibus database under accession number GSE68506 for plasma lncRNA (http://www.ncbi.nlm.nih.gov/projects/geo/index.cgi) and accession number GSE69587 for monocyte lncRNA (http://www. ncbi.nlm.nih.gov/geo/info/linking.html).
Cell culture
THP-1 monocyte, a human acute monocytic leukaemia cell line, was obtained from IBCB (Institute of Biochemistry and Cell Biology, Shanghai, China) and cultured according to the supplier's recommendations at 378C in a humidified 5% (v/v) CO 2 air atmosphere in RPMI 1640 medium (Gibco, Invitrogen) supplemented with 0.1 mg/mL L-glutamine, 0.1 mg/mL streptomycin, 100 U/mL penicillin, and 10% (v/v) foetal calf serum.
Transfection
For transfections, THP-1 monocytes were transferred to fresh medium for 24 h. The cells were transfected using Nucleofector TM Technology (Lonza Group Ltd, Basel, Switzerland), with CoroMarker-specific siRNA (100 nM) or non-silencing siRNA (100 nM) for negative control. Transfection was performed according to the manufacturer's protocol (Lonza, U-001). Subsequently, the transfected cells were seeded into 12-well plates ( 
Results
Patient description
The original microarray cohort consisted of 15 male patients with newly diagnosed CAD and 15 male control subjects who underwent diagnostic coronary angiography for suspected CAD. The baseline characteristics of this population are shown in Supplementary material online, Table S4 . The two groups of patients differed significantly only in the antiplatelet therapy given to CAD patients, with no differences in other clinical or demographic characteristics. In addition to the original microarray cohort, an independent second cohort of 20 CAD patients and control subjects was studied to validate the results obtained in the original cohort. Their clinical and demographic characteristics are summarized in Supplementary material online, Table S5 . These two groups of patients differed significantly only in age (P ¼ 0.040), but not in other characteristics. For further confirmation of CoroMarker expression and the potential relationship between CoroMarker expression and the risk of CAD, we conducted a case -control study. This cohort consisted of 211 cases (CAD patients) and 171 controls (control subjects), who were divided into the training and test sets. The patient characteristics are listed in Supplementary material online, Tables S6  and 1 . Finally, the diagnostic value of CoroMarker in CAD was assessed in another independent set of 50 CAD patients and 40 control subjects. The characteristics of these patients and controls in this independent set are summarized in Table 1 .
Biomarker selection and validation
To determine whether lncRNAs are differentially expressed in CAD patients, we profiled the lncRNA expression in PBMCs and plasma from 15 CAD patients and 15 controls using the 'Human LncRNA Array v2.0 (8660 K, Arraystar)'. The lncRNA profiles from both PBMCs and plasma differed significantly between those two groups, as illustrated in the hierarchical clustering shown in Figure 1 . Of 33 045 lncRNAs detected by the microarrays, 86 lncRNAs were found to be differentially expressed with fold changes greater than 2 and P-values less than 0.05. Of these transcripts, 51 lncRNAs were up-regulated and 35 lncRNAs were down-regulated (see Supplementary material online, Table S3 ). To facilitate the confirmation of the target biomarkers, we chose the up-regulated lncRNAs with the high expression in both PBMCs and plasma as candidate lncRNAs. Among the 51 up-regulated lncRNAs, we used the following criterion to select the possible biomarker candidates: the average normalized intensity should be ≥7 with statistical significance of less than 0.005. After the selection process, only five lncRNAs remained: lncRNA OTTHUMT00000387022, IL21R-AS1, BAT5, AC107016.1, and RP11-203B9.4 (see Supplementary material online, Table S7 ). Circulating blood cells, which can specifically reflect expression profiles related with CAD progression, could serve as appropriate sources for potential biomarkers in the diagnosis and prediction of CAD. 38 We further validated the selected lncRNA expressions in
PBMCs by qPCR. The relative expressions of each lncRNA are shown in Figure 2 . There was a 3.013-fold increase in the expression for lncRNA OTTHUMT00000387022, a 2.524-fold increase for IL21R-AS1, and a 2.217-fold increase for BAT5 in CAD patients when compared with the control subjects. There was no significant difference for AC107016.1 and RP11-203B9.4 between the two groups and hence they were excluded from the candidate list.
Independent validation of lncRNA expression
To further independently validate the increased expressions of lncRNA OTTHUMT00000387022, IL21R-AS1, and BAT5 in CAD patients, we studied by qPCR a second set of PBMC samples from 20 CAD patients and 20 controls. The results showed a 2.807-fold increase in the expression of lncRNA OTTHUMT00000387022, a 2.212-fold increase for IL21R-AS1, and a 2.007-fold increase for BAT5 in CAD patients when compared with the control subjects. These data further confirmed that lncRNA OTTHUMT00000387022, IL21R-AS1, and BAT5 were increased in the PBMCs of patients with CAD ( Figure 3A-C) . We next determined whether lncRNA levels were associated with CAD by performing an ROC curve analysis in the same population. We found that the AUC was 0.940 for lncRNA OTTHUMT00000387022, 0.825 for IL21R-AS1, and 0.818 for BAT5 ( Figure 3D-F) . Taken together, these results indicate that lncRNA OTTHUMT00000387022 in PBMCs may be a good candidate biomarker to predict CAD. Therefore, lncRNA OTTHUMT00000387022 was renamed as CoroMarker. 
Sensitive PBMC CoroMarker for CAD diagnosis
The aforementioned observation was initially performed in a small population. Therefore, we repeated the study in a larger set of CAD patients and controls (211 CAD patients and 171 controls). Figure 4A shows that in this larger cohort, the AUC for CoroMarker was 0.920 with 95% confidence interval (CI) of 0.892-0.947 in the diagnosis of CAD.
To further analyze the diagnostic accuracy of CoroMarker, we constructed a diagnostic model by Fisher criteria; the entire 382 samples were randomly divided into training (161 cases and 121 controls) and test (50 cases and 50 controls) sets. Discriminant function analysis was established using the Fisher criteria with the training set, validated by the test set. The training set was selected randomly in the original set with uniform distribution each time, and repeated for 100 times, and chose the optimal discriminant function, which corresponded to the 15th training set, as the final discriminant factor. The AUC was 0.905 and 95% CI 0.869-0.940 ( Figure 4B) . The signature was defined as follows: f ¼ 23.052 x + 4.649, where 'x' denoted the expression level of CoroMarker and a patient was classified as 'CAD' if f , 0, according to the patient's lncRNA expression value. The cutoff number was 1.523 for CAD, i.e. patients with cutoff number greater than 1.523 were classified as CAD patients. The characteristics of the training set of patients are shown in Table 1 ; the two groups of patients in the training set differed significantly in age, arterial hypertension, smoking habits, and AT 1 receptor blocker, calcium channel blocker, beta-blocker, and antiplatelet therapy, but not in other clinical and pathological variables.
The lncRNA signature was then validated for its diagnostic accuracy in a test set (50 cases and 50 controls, respectively). As for patients in the training set, the basic characteristics of patients in the test set are listed in Table 1 . The same model and criteria were used as those in the training set. Repeated 100 times, the average classification numbers were 42 and 58 for those with or without CAD, respectively; the corresponding average sensitivity and specificity for the diagnosis of CAD were 64.000 and 80.000%, respectively (see Supplementary material online, Table S8 -1). The optimal classification number (15th time) for those with or without CAD was 40 and 49, respectively; the corresponding optimal sensitivity and specificity were 80.00 and 98.00%, respectively (see Supplementary material online, Table S8 -2). The AUC was 0.960 and 95% CI 0.923 -0.997 ( Figure 4C ). 
Predictive value of CoroMarker vs. traditional risk factors for CAD
To show the diagnostic value of CoroMarker, we compared it with traditional risk factors by Bayesian analysis and McNemar test. The pretest probability variables required prior calculation and given a number of 0 or 1. P(C1) denoted the pre-test probability for CAD and P(C2) for controls. The pre-test probability P(C1) was 0.571 and P(C2) was 0.429. The pre-test probability is shown in the Supplementary material online, Table S9 . The signature was defined as follows: where 'x k ' denoted the pre-test probability of each variable. A patient was classified as CAD when f 1 (x)≥f 2 (x) , and as 'control' when f 1 (x),f 2 (x), according to the pre-test probability variables. The McNemar test showed that the traditional risk factors correctly classified 43 and 42 into the CAD patients and control subjects, respectively; the diagnostic accuracy was 0.85. Then, we compared the predictive value of CoroMarker discriminant function vs. traditional risk factors by the McNemar test. The results are shown in Supplementary material online, Table S10 What's more is to show whether or not these known risk factors have an additive effect on the prediction values of the PBMC CoroMarker level. We re-performed the Bayesian model of CoroMarker plus traditional risk factors in the same training group of the Fisher model, and we re-constructed the diagnostic model by Bayesian analysis, with the same method and criteria as mentioned earlier, the signature was:
where x k denoted the pre-test probability of each risk factor. A patient was classified as CAD if f 1 (x)≥f 2 (x) and as controlif f 1 (x),f 2 (x), according to the pre-test probability variables. The combination of CoroMarker with traditional risk factors correctly classified 42 and 44 into the CAD patients and control subjects, respectively; the diagnostic accuracy was 0.86. We also compared the predictive value of CoroMarker plus traditional risk factors vs. CoroMarker only by the McNemar test. The results are shown in Supplementary material online, Table S11 ; 34 CAD patients and 45 controls were identified by either CoroMarker plus traditional risk factors or CoroMarker only. The diagnostic accuracy of CoroMarker plus traditional risk factors (0.86) was not prior to that of CoroMarker only (0.89) (x 2 Mc = 1.532, P ¼ 0.216).
Independence of CoroMarker on CAD risk factors and other CVDs
CAD has many risk factors, including age, sex, BMI, hypertension, hyperlipidaemia, diabetes mellitus, and degree of coronary artery obstruction. Whether or not CoroMarker is independent of those CAD risk factors is not known. Our present study analysed the relationship between CoroMarker and those CAD risk factors by using the Kruskal -Wallis H-and Mann -Whitney U-tests. The results from the original and training sets indicated that CoroMarker expression was not correlated with the aforementioned risk factors and medication history (statins, angiotensin II-converting enzyme inhibitors, AT 1 receptor blockers, calcium channel blockers, beta-adrenergic blockers, and antiplatelet agents) (see Supplementary material online, Table S12 ). To assess whether the prediction ability of CoroMarker is independent of other clinical risk factors of the patients with CAD, multivariable regression analysis was performed using a stepwise variable selection method. Selected covariables included age, hypertension, LDL, symptoms, family history, and CoroMarker (see Supplementary material online, Table S13 ). The results showed that CoroMarker was an independent risk factor for patients with CAD. The results clearly indicated that the presence of CoroMarker could be used to separate CAD patients from control subjects and not influenced by CAD risk factors.
To further show diagnostic specificity, we also tested the CoroMarker levels in PBMCs from patients with other CVDs, including atrial fibrillation, valvular disease, dilated cardiomyopathy, peripheral artery disease, hyperlipidaemia, diabetes mellitus, abdominal aortic aneurysm, and viral myocarditis, according to the ACC/AHA classification. The results showed that PBMC CoroMarker levels in those patients were not different from those with normal coronary vessels, the controls ( Figure 5 ).
Application of CoroMarker in the discriminative diagnosis in patients clinically suspected to have CAD
We further validated the diagnostic accuracy of CoroMarker for CAD prediction in a prospective fashion, using 90 clinically suspected cases of CAD. First, we analysed the value of CoroMarker and classified them on the basis of the aforementioned discriminant function. All 90 cases were then monitored and CAD determined by coronary angiography. The two angiogram readers were blinded to the patient's CoroMarker values. Results from the final angiography diagnosis served as the standard to test the accuracy of CoroMarker profile alone for CAD diagnosis. As shown in Supplementary material online, Table S14 , CoroMarker correctly classified patients into 38 cases and 37 controls; the corresponding optimal sensitivity and specificity values were 76 and 92.5%, respectively.
Functional enrichment analysis of genes correlated with the signature lncRNA
We next sought to explore the potential role of CoroMarker in the pathogenesis of CAD. The correlation between the PBMC CoroMarker and mRNAs was studied from the same microarray cohort of 15 CAD patients and 15 control subjects. It showed that expressions of 35 protein-coding genes were positively correlated (Pearson's correlation coefficient ≥0.990 and FDR ≤7.61E205) with CoroMarker, whereas the expressions of 33 genes were negatively correlated with CoroMarker (Pearson's correlation coefficient ≤0.900, FDR ≤9.83E205). Those positively correlated genes were associated with signal transduction transmembrane transport and synaptic transmission in the gene ontology (GO) biological process enrichment analysis (see Supplementary material online, Table S15 ). Using the same method of analysis, the negatively correlated genes were clustered with innate immune response, cytokine-mediated signalling, and apoptotic process-mediated signalling pathways (see Supplementary material online, Table S16 ). These results suggested that CoroMarker may positively regulate genes that affect the formation of foam cells and AS and repress genes that affect apoptosis, inflammation, and immunity activity.
3.9 IL-1b, IL-6, and TNF-a determinations in culture medium of THP-1 cells
The presence of the proinflammatory cytokines IL-1b, IL-6, and TNF-a was determined by ELISA in the culture media of THP-1 cells that were untreated controls and THP-1 cells transfected with the non-silencing siRNA or CoroMarker-specific siRNA (100 nM for 48 h). When compared with the control group, no significant changes in cytokine levels were observed in the negative control group. However, in the CoroMarker-specific siRNA group, the cytokine levels in the culture medium were reduced significantly ( Figure 6 ).
Discussion
Despite great advances in modern medicine, the diagnosis of CAD still remains difficult, especially in its earlier stages. Herein, the utility of multimarker panels in the diagnosis of CAD was scored to help solve this problem. We found that a panel consisting of 10 plasma-derived inflammatory biomarkers, including homocysteine, IL-6, C-reactive protein, and other well-known risk factors, showed only marginal improvement in its diagnostic value, relative to the diagnostic value of each risk factor. 39 -41 Therefore, a novel class of biomarkers for CAD is urgently needed. LncRNAs belong to a novel class of non-coding RNAs with more than 200 nucleotides. Previous studies showed that lncRNAs are involved in fundamental cellular processes such as RNA processing, 42 gene regulation, 43 25 HOTAIR, 49 and XIST, 50 have been clarified to some extent. Some lncRNAs have been reported to be biomarkers for the diagnosis and poor prognosis for cancers. For example, the lncRNA metastasis associated with lung adenocarcinoma transcript 1 (MALAT-1) has been reported as a plasma-based biomarker for the diagnosis of prostate cancer. 51 Increased levels of the lncRNA HOTAIR denotes poor prognosis in colorectal cancer, 52 and decreased expression of the lncRNA GAS5 denotes poor prognosis in gastric cancer. 53 Moreover, altered expressions of lncRNAs have been reported in CAD, such as ANRIL, 24 lincRNA-P21, 47 and MIAT-1 and may indicate a possible relationship between lncRNAs and the pathogenesis of CAD. By microarray screening and validation with qPCR in different groups of patients, we found that CoroMarker is a novel biomarker with a high sensitivity and specificity for the diagnosis of CAD. For the statistical analysis of high-throughput biological data, we used several strategies to reduce the problems associated with small sample sizes to classify very large number of genes. First, 86 lncRNAs expressed differentially in both PBMCs and plasma between patients with and without CAD were filtered out and then subjected to reclassification in order to further narrow down the number of candidates. To facilitate the confirmation of target biomarkers, we chose the up-regulated lncRNAs with high expression in both PBMCs and plasma as candidate lncRNAs. Among the 51 up-regulated lncRNAs, only 25 lncRNA transcripts had an average normalized intensity of ≥7. Further filtering of the remaining 25 lncRNAs using the criterion of P , 0.005 reduced the candidate lncRNAs to 5. The expressions of these five lncRNAs were verified by qPCR. Two, which were not different between the CAD and control patients, were excluded from the candidate list. We validated and further defined these three lncRNAs using the ROC curve analysis; only the AUC of CoroMarker was up to 0.940. Thus, CoroMarker was selected as the best candidate to diagnose CAD.
The functions of most lncRNAs have not yet been annotated. However, we can infer their possible functions by the clues from the mRNA expressions in the same microarray. We found that genes whose expression values positively correlate with CoroMarker are enriched for the GO biological process term 'signal transduction, metabolic process and transcription, DNA-dependent' (see Supplementary material online, Table S15 ). It is noted that some of the related genes that correlated with CoroMarker have already been reported to have proatherogenic functions. For instance, IL15RA (NC 000010.11), IL-15 receptor alpha, is a proinflammatory cytokine that modulates T cell recruitment and activation during atherogenesis. 54 Another gene clustered into the same GO term, ADORA1 (NC_000001.11), coding adenosine A1 receptor, is also a well-studied gene involved in the pathogenesis of CAD. 55 Moreover, the negatively correlated genes clustered in the 'apoptotic process, inflammatory response, and small molecule metabolic process' (see Supplementary material online, Table S16 ); some of these genes have already been reported to have anti-atherogenic function. For example, BAX (NC_000019.10), BCL2-associated X protein, clustered into the GO term 'apoptotic process'; these pro-apoptotic molecules in CD4 + CD28 null T cells are reduced in patients with acute coronary syndrome. 56 Another gene clustered into the GO term 'small molecule metabolic process', GSTT1, glutathione S-transferase theta 1, plays a key role in the protection of against oxidative stress-related AS. 57 We validated the function of CoroMarker in THP-1 cells; specific siRNA treatment reduced the levels of the proinflammatory cytokines IL-1b, IL-6, and TNF-a in the culture medium. The results indicate that CoroMarker plays an important role in the inflammatory process involved in atherogenesis. Although CAD and peripheral artery disease share some common mechanisms, including foam cell formation and inflammation, our previous study found that there was no correlation in the stenosis in coronary and other arteries. 58 The reason for this difference between coronary and other arteries is not known, which needs to be determined in the future. This study has some limitations; for example, the studies were conducted in a population who underwent coronary angiography. Whether or not CoroMarker has similar diagnostic values in other patients suspected to suffer from CAD, e.g. no chest pain, remains to be determined. Although the predictive value of CoroMarker for CAD was generated and tested in a relatively large cohort of patients and the patients enrolled in the study were from different regions in China, using data sets from other institutes, the value of CoroMarker in the diagnosis of CAD will have to be determined in patients from other countries and other races and even larger numbers of study subjects.
In conclusion, our study has shown that the lncRNA expression profile is altered in the PBMCs and plasma from CAD patients; CoroMarker is a novel biomarker with high sensitivity and specificity for the diagnosis of CAD.
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